Evidências científicas sobre o uso de novas drogas psicodélicas no tratamento da depressão resistente

Psychedelic drugs are emerging as promising alternatives for treating resistant depression, where many patients do not respond to conventional therapies. A systematic review of scientific articles from 2015 to 2025 will analyze clinical studies, randomized controlled trials, and systematic reviews on neurobiological mechanisms, therapeutic outcomes, adverse effects, and ethical aspects. The research aims to consolidate knowledge on efficacy and safety, highlighting clinical advances and limitations, to support mental health professionals and policy makers. It also seeks to destigmatize medicinal psychedelic use and encourage evidence-based practices to improve quality of life for patients with resistant depression.

Study at a glance

Abstract

The treatment of resistant depression represents a significant challenge in psychiatry, as a considerable portion of patients do not adequately respond to conventional therapies. In this context, new psychedelic drugs have emerged as promising therapeutic alternatives, garnering increasing interest from the scientific and clinical community. The overall objective of this research is to analyze the scientific evidence regarding the efficacy and safety of using these substances in the treatment of resistant depression. To this end, a systematic literature review will be conducted, with search and critical analysis of recent scientific articles published between 2015 and 2025 in databases such as PubMed, SciELO, and Google Scholar. The methodology involves the selection of clinical studies, randomized controlled trials, and systematic reviews that address the neurobiological mechanisms, therapeutic outcomes, adverse effects, and ethical aspects involved in the use of psychedelics. It is expected that this research will contribute to the consolidation of scientific knowledge on the subject, presenting an integrated view of clinical advances and existing limitations, providing support for mental health professionals, researchers, and public policy makers. Furthermore, a critical analysis of the evidence may broaden the debate on effective alternatives for patients who do not respond to traditional treatments, in addition to promoting the destigmatization of the medicinal use of psychedelics and encouraging the adoption of evidence-based practices. Thereby, it is intended to contribute to the advancement of contemporary psychiatry, fostering the development of innovative and safe therapies that can improve the quality of life of patients with resistant depression.